10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does 10x Genomics (TXG) Have the Potential to Rally 85.65% as Wall Street Analysts Expect?
The consensus price target hints at an 85.7% upside potential for 10x Genomics (TXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?
10x Genomics (TXG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
10x Genomics: Sticking To The Plan To Avoid The Falling The Knife
10x Genomics has experienced a significant decline in share price, currently trading around $20 per share, with no bullish indicators for a potential reversal. Recent performance shows growth in total revenue to $141M, but with a decrease in consumables revenue and a rise in operating costs, leading to an operating loss. Factors contributing to the decline in TXG include economic influences, fading growth prospects, supply chain issues, legal battles with NanoString Technologies, and a lack of retail investor interest.
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of 10x Genomics, Inc. (NASDAQ: TXG) and Encourages Investors to Contact the Firm
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating 10x Genomics, Inc. (NASDAQ:TXG) on behalf of the company's stockholders. The investigation seeks to determine whether 10x Genomics and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors in connection with recent corporate actions.
